Abstract
The cannabinoid signaling system regulates intraocular pressure (IOP) in the mouse via a complex system that includes three receptors: CB1, GPR18 and GPR119. In each case, activating the receptor lowers IOP, but CB1 receptors are found both at sites of aqueous humor inflow and outflow. As such, knockout mice for any of these receptors would be expected to have higher-than average, or at least unchanged, intraocular pressure. The current study investigates the unexpected observation that CB1 knockout mice have lower pressure than wild type counterparts by testing various regulators of cannabinoid signaling in murine models of IOP. We now report that a CB1 antagonist has differential effects on IOP: SR141716 raises IOP in standard light cycle (SLC) but lowers IOP in reverse light cycle (RLC). This is mimicked by ABD1085, a negative allosteric modulator of CB1. CB1 inhibitors lower IOP in both normotensive and hypertensive mouse eyes. The pressure-lowering effect is absent in CB1 knockout mice. IOP rebounds after the end of treatment but shows no sign of desensitization with daily treatment for a week. Unlike the positive cannabinoid effect, antagonist effects are not sex-dependent. We propose that there are two mechanisms of action for CB1, one that lowers IOP upon activation and a second with inverse sign that lowers IOP when CB1 is antagonized. The relatively lower pressure in CB1 knockout mouse eyes suggests that this second negative regulation of IOP is dominant.
Keywords: Antagonist, CB1, Cannabinoid, Glaucoma, Ocular pressure
Copyright © 2020. Published by Elsevier Ltd.
Similar articles
-
Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5904-5911. doi: 10.1167/iovs.18-24838.PMID: 30550613 Free PMC article.
-
The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. doi: 10.1089/jop.2017.0037. Epub 2017 Jul 18.PMID: 28719234 Free PMC article.
-
Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.Pharmaceuticals (Basel). 2018 May 22;11(2):50. doi: 10.3390/ph11020050.PMID: 29786643 Free PMC article.
-
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.Curr Drug Targets. 2010 Aug;11(8):978-93. doi: 10.2174/138945010791591278.PMID: 20426763 Review.
-
Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.Exp Eye Res. 2017 May;158:23-32. doi: 10.1016/j.exer.2016.08.023. Epub 2016 Sep 1.PMID: 27593914 Free PMC article. Review.